Abstract
The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.
Original language | English |
---|---|
Pages (from-to) | 811-812 |
Number of pages | 2 |
Journal | Nature Reviews Drug Discovery |
Volume | 16 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2017 |
Keywords
- Drug Evaluation, Preclinical
- Drug Industry
- Drug-Related Side Effects and Adverse Reactions
- Humans
- Information Dissemination
- Journal Article
- Risk Assessment